According to the associated press, gunshots rang out near the government building in Kiev, Ukraine.

China's First Oral COVID-19 Antiviral Medicine in Dispute

An obscure Chinese company called Genuine Biotech(Chinese: 真实生物) was suddenly put under the spotlight on July 25 when the Chinese authority announced the conditional approval of the company's application for adding the treatment of COVID-19 as a new indication of Azvudine under the special review and approval procedures for drug registration.

Chinese Retail Firm Meituan’s Revenue Sees 26.7% Bump in Q1 2023, Reaching CNY 58.6 Bn

In the first quarter of 2023, Meituan continued to further promote its "Retail + Technology" strategy to increase its investment in China's consumer market, with R&D spending increasing to CNY 5 billion.

Chinese Carmaker Xpeng’s Revenue in Q1 2023 Exceeds CNY 4.03 Bn, Down 45.9% YoY

The G6 will be officially released in June, with mass deliveries beginning in July and rapidly increasing. The G6 is expected to propel Xpeng's overall deliveries to a much above-industry growth rate in the third quarter, representing the first sales inflection point following Xpeng's strategic and organizational improvements.

China’s Smartphone Giant Xiaomi's Revenue in Q1 2023 Exceeds CNY 59.48 Bn, Down 18.9% YoY

In 2023, Xiaomi’s overall business mode will shift from scale expansion to quality enhancement. According to the financial report for Q1 2023, Xiaomi's overall inventory amounted to CNY 42.6 billion, a decrease of over 24% from the same period last year, achieving three consecutive quarters of decline, and the lowest level in the past nine quarters.

Junshi Biosciences Receives NMPA Approval of sNDA for Toripalimab

The study data showed that compared to chemotherapy alone, toripalimab in combination with chemotherapy in the first-line treatment of patients with advanced NSCLC without EGFR/ALK mutations could significantly improve the PFS and the OS of patients with a manageable safety profile regardless of PD-L1 expression status.